Trial Profile
NANT Pancreatic Cancer Vaccine: Combination Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 04 Aug 2022
Price :
$35
*
At a glance
- Drugs CST 101 (Primary) ; ETBX 011 (Primary) ; GI 4000 (Primary) ; Inbakicept (Primary) ; Avelumab; Bevacizumab; Capecitabine; Cyclophosphamide; Fluorouracil; Folinic acid; Oxaliplatin; Paclitaxel
- Indications Pancreatic cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors ImmunityBio; NantKwest
- 10 Aug 2020 Planned End Date changed from 1 Dec 2018 to 1 Apr 2021.
- 10 Aug 2020 Planned primary completion date changed from 1 Oct 2018 to 1 Dec 2020.
- 04 Jan 2018 Status changed from recruiting to active, no longer recruiting.